Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1141-1148

  Tzitzivacos, D B ^a   Tiemessen, C T ^b   Stevens, W S ^a   Papathanasopoulos, M A ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; VPR PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DISEASE COURSE; ENDOCYTOSIS; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOME; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; VIRUS ISOLATION;

ANTI-HIV AGENTS; CHILD; DNA, VIRAL; FEMALE; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

EID: 71949103127     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0080     Document Type: Article

References (72)

1. Lama J and Planelles V: Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 2007;4:p52.
2. Pantaleo G, Graziosi C, and Fauci AS: New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-335. (Pubitemid 23035333)
3. Langford SE, Ananworanich J, and Cooper DA: Predictors of disease progression in HIV infection: A review. AIDS Res Ther 2007;4:11.
4. Pantaleo G and Fauci AS: Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996;50:825-854.
5. Learmont J, Tindall B, Evans L, et al.: Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992;340:863-867.
6. Walker BD: Elite control of HIV infection: Implications for vaccines and treatments. Top HIV Med 2007;15:134-136.
7. Saloojee H and Violari A: HIV infection in children. BMJ 2001;323:670-674.
8. Little K, Thorne, C Luo C, et al.: Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: Reviewing the need for HIV treatment. Curr HIV Res 2007;5:139-153.
9. Paul ME: The immune system in vertical HIV infection: The immune response and disease progression. AIDS Res Hum Retroviruses 1997;13:1-4.
10. Warszawski J, Lechenadec J, Faye A, et al.: Long-term nonprogression of HIV infection in children: Evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis 2007;45(6):785-794.
11. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1 specific CD4+T cell responses associated with control of viremia. Science 1997;278:1447-1450.
12. Cecilia D, Kleeberger C, Munoz A, et al.: A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 1999;179:1365-1374.
13. Greenough TC, Brettler DB, Somasundaran M, et al.: Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo. J Infect Dis 1997;176:118-125.
14. Carrington M and O'Brien SJ: The influence of HLA genotype on AIDS. Annu Rev Med 2003;54:535-551.
15. Fellay J, Shianna KV, Ge D, et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-947.
16. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiplyexposed individuals to HIV-1 infection. Cell 1996;86:367-377.
17. Fauci AS: Resistance to HIV-1 infection: It's in the genes. Nat Med 1996;2:966-967.
18. An P, Bleiber G, Duggal P, et al.: APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004;78:11070-11076.
19. Kanki PJ, Hamel DJ, Sankale JL, et al.: Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
20. Kaleebu P, French N, Mahe C, et al.: Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002;185:1244-1250.
21. Kiwanuka N, Laeyendecker O, Robb M, et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197:707-713.
22. Kirchhoff F, Greenough TC, Brettler DB, et al.: Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-232.
23. Deacon NJ, Tsykin A, Solomon A, et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
24. Oelrichs R, Tsykin A, Rhodes D, et al.: Genomic sequence of HIV Type 1 from four members of the Sydney Blood Bank Cohort of long-term nonprogressors. AIDS Res Hum Retroviruses 1998;14:811-814.
25. Salvi R, Garbuglia AR, Di Caro A, et al.: Grossly defective nef gene sequences in a human immunodeficiency virus type-1 seropositive long-term nonprogressor. J Virol 1998; 72:3646-3657.
26. Brambilla A, Turchetto L, Gatti A, et al.: Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology 1999;259:349-368.
27. Walker PR, Ketunuti M, Choge IA, et al.: Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses 2007;23:204-215.
28. Kondo M, Shima T, Nishizawa M, et al.: Identification of attenuated variants of HIV-1 circulating recombinant form 01-AE that are associated with slow disease progression due to gross genetic alterations in the nef=long terminal repeat sequences. J Infect Dis 2005;192:56-61.
29. Verity EE, Zotos D, Wilson K, et al.: Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J Virol 2007;81:9268-9278.
30. Crotti A, Neri F, Corti D, et al.: Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation. J Virol 2006;80:10663-10674.
31. Tobiume M, Takahoko M, Yamada T, et al.: Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors. J Virol 2002;76:5959-5965.
32. Catucci M, Venturi G, Romano L, et al.: Analysis of the HIV-1 nef gene in five intravenous drug users with long term nonprogressive HIV-1 infection in Italy. J Med Virol 2000;60: 294-299.
33. Huang Y, Zhang L, and Ho DD: Characterization of gag and pol sequences from long-term survivors of human immunodeficiency type 1 infection. Virology 1998;240:36-49.
34. Wang B, Chun Ge Y, Palasanthiran P, et al.: Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in longterm nonprogressing mother and child pair: In vivo evolution of vpr quasispecies in blood and plasma. Virology 1996;223:224-232.
35. Iversen AKN, Shpaer EG, Rodrigo AG, et al.: Persistence of attenuated rev genes in a human immunodeficiency virus type-1 infected asymptomatic individual. J Virol 1995;69: 5743-5753.
36. Yamada T and Iwamoto A: Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000;145:1021-1027.
37. Alexander L, Aquino-DeJesus MJ, Chan M, et al.: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol 2002;76:10533-10539.
38. Papathanasopoulos MA, Patience T, Meyers TM, et al.: Fulllength genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses 2003;19:1033-1037.
39. Churchill MJ, Chiavaroli L, Wesselingh SL, et al.: Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nefdeleted virus. Retrovirology 2007;4:43.
40. Cho YK and Yung YS: High frequency of gross deletions in the 5 LTR and gag regions in HIV type 1-infected long-term survivors treated with Korean red ginseng. AIDS Res Hum Retroviruses 2008;24:181-193.
41. Mologni D, Citterio P, Menzaghi B, et al.: Vpr and HIV-1 disease progression: R77Q mutation is associated with longterm control of HIV-1 infection in different groups of patients. AIDS 2006;20:567-574.
42. Rajan D, Wildum S, Rucker E, et al.: Effect of R77Q, R77A and R80A changes in Vpr on HIV-1 replication and CD4 T cell depletion in human lymphoid tissue ex vivo. AIDS 2006;20:831-836.
43. Rodes B, Toro C, Paxinos E, et al.: Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004;18:1109-1116.
44. Wang B, Spira TJ, Owen S, et al.: HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. AIDS 2000;14:213-223.
45. Alexander L, Weiskopf E, Greenough TC, et al.: Unusual polymorphisms in human immunodeficiency type 1 associated with nonprogressive infection. J Virol 2000;74:4361-4376.
46. Choge I, Cilliers T, Walker P, et al.: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006;22:458-465.
47. Rousseau CM, Birditt BA, McKaya AR, et al.: Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods 2006;136:118-125.
48. Larder BA, Hertogs K, Bloor S, et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000;14:1943-1948.
49. Harris D and Engelman A: Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro. J Biol Chem 2000;275:39671-39677.
50. Kalpana GV, Marmon S, Wang, W, et al.: Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994;266(5193):2002-2006.
51. Rahman S, Lu R, Vandegraaff N, et al.: Structure-based mutagenesis of the integrase-LEDGF=p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology 2007;357:79-90.
52. Roth MJ, Schwartzberg PL, and Goff SP: Structure of the termini of DNA intermediates in the integration of retroviral DNA: Dependence on IN function and terminal DNA sequence. Cell 1989;58:47-54.
53. Faure A, Calmels C, Desjobert C, et al.: HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res 2005;33:977-986.
54. Schroder AR, Shinn P, Chen H, et al.: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-529.
55. Carteau S, Hoffmann C, and Bushman F: Chromosome structure and human immunodeficiency virus type 1 cDNA integration: Centromeric alphoid repeats are a disfavored target. J Virol 1998;72:4005-4014.
56. Cui J, Tangaturthi PK, Ayyavoo V, et al.: The role of Vpr in the regulation of HIV-1 gene expression. Cell Cycle 2006;5: 2626-2638.
57. Tungaturthi PK, Sawaya BE, AyyavooV, et al.: HIV-1 Vpr: Genetic diversity and functional features from the perspective of structure. DNA Cell Biol 2004;23:207-222.
58. Lum JJ, Cohen OJ, Nie Z, et al.: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003;111:1547-1554.
59. Brenner C and Kroemer G: The mitochondriotoxic domain of Vpr determines HIV-1 virulence. J Clin Invest 2003;111: 1455-1457.
60. Jones GJ, Barsby NL, Cohen EA, et al.: HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007;27:3703-3711.
61. Thomas ER, Dunfee RL, Stanton J, et al.: High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia. AIDS Res Hum Retroviruses 2007;23:575-580.
62. Bannwarth S and Gatignol A: HIV-1 TAR RNA: The target of molecular interactions between the virus and its host. Curr HIV Res 2005;3:61-71.
63. Harrich D, McMillan N, Munoz L, et al.: Will diverse Tat interactions lead to novel antiretroviral drug targets? Curr Drug Targets 2006;7:1595-1606.
64. Izmailova E, Bertley FM, Huang Q, et al.: HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003;9:191-197.
65. Peruzzi F: The multiple functions of HIV-1 Tat: Proliferation versus apoptosis. Front Biosci 2006;11:708-717.
66. Sabatier JM, Vives E, Mabrouk K, et al.: Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 1991;5:961-967.
67. Xiao H, Neuveut C, Benkirane M, and Jeang KT: Interaction of the second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-mediated shut-off of host mRNA translation. Biochem Biophys Res Commun 1998;244:384-389.
68. Cochrane A: Controlling HIV-1 Rev function. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:287-295.
69. Ramakrishnan R, Hussain M, Holzer, A, et al.: Evaluations of HIV type 1 rev gene diversity and functional domains following perinatal transmission. AIDS Res Hum Retroviruses 2005;21:1035-1045.
70. Das SR and Jameel S: Biology of the HIV Nef protein. Indian J Med Res 2005;121:315-332.
71. Ueno T, Idegami Y, Motozono C, et al.: Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs. J Immunol 2007;178:5513-5523.
72. Meddows-Taylor S, Papathanasopoulos MA, Kuhn L, Meyers TM, and Tiemessen CT: Detection of human immunodeficiency virus type 1 envelope peptide-stimulated T-helper cell responses and variations in the corresponding regions of viral isolates among vertically infected children. Virus Genes 2004;28:311-318.